Collaboration with Sohin Genetics

Summary by AI ^BETAClose X

GENinCode Plc has announced a commercial agreement with Sohin Genetics in Mexico to distribute its CARDIO inCode-Score® Polygenic Risk Score test, aimed at predicting and preventing coronary heart disease. This collaboration targets Mexico's significant cardiovascular disease market, estimated at USD $4.3 billion, where heart disease is the leading cause of death. Sohin Genetics will promote and market the test across its network of hospitals and clinics, leveraging GENinCode's SITAB international reporting system. This expansion into Mexico follows GENinCode's recent collaboration with AMPAC, further strengthening its presence in the growing cardiovascular disease prevention sector.

Disclaimer*

GENinCode PLC

17 December 2025

GENinCode Plc

("GENinCode" or the "Company")

CARDIO inCode-Score® distribution with Sohin Genetics, Mexico

Commercial agreement to distribute CARDIO inCode-Score®

for the genetic risk prediction and prevention of coronary heart disease

GENinCode Plc (AIM: GENI), the Oxford based predictive genetics company focused on the prevention of cardiovascular disease ("CVD") and risk assessment of ovarian cancer, announces today a collaboration with Sohin Genetics, Mexico to distribute the CARDIO inCode-Score® Polygenic Risk Score ("PRS") test for the prevention of coronary heart disease ("CHD" or "heart disease").

This announcement follows the recent collaboration between GENinCode and "AMPAC" (Mexican Association for the prevention of Atherosclerosis) dedicated to research, education and promotion of healthy lifetstyles to combat atherosclerosis and heart disease in Mexico.

Sohin Genetics provide integrated healthcare services, especially in diagnostics, to deliver precision medicine access across their network of hospitals and clinics. Sohin Genetics will commercially promote and market CARDIO inCode-Score in the Mexican market including training, sample handling and ordering via the GENinCode 'SITAB' international reporting system. Mexico has a population of over 130 million with an estimated cardiovascular disease market of USD$ 4.3 billion with coronary heart disease the leading cause of death.

CARDIO inCode-Score® (PRS)

CARDIO inCode-Score is a clinically validated, commercially available polygenic risk score (PRS) based on DNA extracted from a simple saliva or blood sample. The extracted DNA is scored to identify an individual's inherited genetic risk of heart disease thereby enabling prevention through lifestyle change and/or therapeutic treatment. The test has been designed and optimized for population-based risk prediction and primary prevention of heart disease and is being made available at affordable pricing to international healthcare systems.

By integrating CARDIO inCode-Score® into existing clinical pathways, healthcare providers can more accurately identify individuals at heightened 'lifetime risk' of heart disease and personalise treatment and prevention strategies. This preventive approach reduces the incidence of severe cardiovascular events, such as heart attacks and strokes, and mitigates the economic costs associated with long-term heart disease care. It represents a significant step to improving public health outcomes and particularly in addressing the global burden of cardiovascular disease.

Matthew Walls, GENinCode Chief Executive Officer said; "We are delighted to announce this latest distribution agreement with Sohin Genetics to sell CARDIO inCode-Score in Mexico. The collaboration will extend our reach into this growing cardiovascular disease market and allow us to consider other tests for distribution in the region."

For more information visit www.genincode.com

Enquiries:

GENinCode Plc	www.genincode.com or via Walbrook PR
Matthew Walls, CEO

Cavendish Capital Markets Limited			Tel: +44 (0)20 7397 8900
Giles Balleny (Corporate Finance)
Nigel Birks (Life Sciences Specialist Sales)
Harriet Ward (Corporate Broking)
Dale Bellis / Michael Johnson (Sales)

Walbrook PR Limited
Anna Dunphy / Marcus Ulker		Tel: 020 7933 8780 or genincode@walbrookpr.com

Notes for editors

Coronary Heart Disease

Coronary Heart Disease ("CHD"), is the leading cause of death globally and is responsible for approx. 9 million deaths annually and estimated to affect over 250 million people suffering with symptoms of CHD¹. In the UK, it is the most common form of death and disability, with approximately 2.3 million people living with the condition².

CHD occurs when the coronary arteries, which supply blood to the heart, become narrowed by build-up of fatty materials (cholesterol and other lipids) which give rise to what is commonly known as atherosclerosis or heart disease. Atherosclerosis restricts blood flow to the heart causing symptoms like angina (chest pain) with increasing atherosclerosis burden giving rise to heart attack (or ischemic stroke) if the artery becomes completely blocked by a blood clot.

^1. World Health Organisation - www.who.int - The leading causes of death

^2. British Heart Foundation - www.bhf.org.uk - Statistics

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END